← All trials
NCT06635135
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 19, 2024
- Primary completion
- May 13, 2027
- Completion date
- May 13, 2027
- First posted
- Oct 10, 2024
- Last posted
- Oct 24, 2024
- Enrollment
- 660
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.